We want to thank Genotypic Technology Pvt. Ltd., Bangalore, for providing us the microarray facility. The authors thank the hospital staff at the Kala-azar Medical Research Centre, Muzaffarpur, for their assistance in the collection of patient samples. We especially thank Dr. Rajiv Kumar and Neetu Singh for their support. The authors thank Dr. Phillip Lawyer for revising the manuscript for language and grammatical check.
Sundar S, More DK, Singh MK, Singh VP, Sharma S, Makharia A, Kumar PC, Murray HW, 2000. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis 31: 1104–1107.
WHO, 2005. Regional Strategic Framework for Elimination of Kala-azar from the South-East Asia Region (2005–2015). New Delhi: Regional Office for South-East Asia SEA-VBC-85 (Rev-1). Geneva, Switzerland: World Health Organization.
Sundar S, Olliaro PL, 2007. Miltefosine in the treatment of leishmaniasis: clinical evidence for informed clinical risk management. Ther Clin Risk Manag 3: 733–740.
Sundar S, Singh A, Rai M, Prajapati VK, Singh AK, Ostyn B, Boelaert M, Dujardin JC, Chakravarty J, 2012. Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use. Clin Infect Dis 55: 543–550.
Hefnawy A, Berg M, Dujardin JC, De Muylder G, 2016. Exploiting knowledge on Leishmania drug resistance to support the quest for new drugs. Trends Parasitol 33: 162–174.
Downing T 2011. Whole genome sequencing of multiple Leishmania donovani clinical isolates provides insights into population structure and mechanisms of drug resistance. Genome Res 21: 2143–2156.
Edgar R, Domrachev M, Lash AE, 2002. Gene expression omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 30: 207–210.
Deborggraeve S, Boelaert M, Rijal S, De Doncker S, Dujardin JC, Herdewijn P, Buscher P, 2008. Diagnostic accuracy of a new Leishmania PCR for clinical visceral leishmaniasis in Nepal and its role in diagnosis of disease. Trop Med Int Health 13: 1378–1383.
Livak KJ, Schmittgen TD, 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402–408.
Kumar D, Tiwary P, Dube A, Chakravarty J, Rai M, Sundar S, 2013. Cloning, expression and purification of L. donovani specific antigen for serodiagnosis of visceral leishmaniasis. J Mol Biomark Diagn 4: 1000141.
Rijal S 2013. Increasing failure of miltefosine in the treatment of kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance. Clin Infect Dis 56: 1530–1538.
Rahman M 2011. Phase IV trial of miltefosine in adults and children for treatment of visceral leishmaniasis (kala-azar) in Bangladesh. Am J Trop Med Hyg 85: 66–69.
Biomarkers Definitions Working Group, 2001. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69: 89–95.
Hertz-Fowler C, Ersfeld K, Gull K, 2001. CAP5.5, a life-cycle-regulated, cytoskeleton-associated protein is a member of a novel family of calpain-related proteins in Trypanosoma brucei. Mol Biochem Parasitol 116: 25–34.
Frame MJ, Mottram JC, Coombs GH, 2000. Analysis of the roles of cysteine proteinases of Leishmania mexicana in the host-parasite interaction. Parasitology 121: 367–377.